Project Farma’s John Khoury joined Jason C. Foster of Ori Biotech for an insightful conversation on what’s shaping the “new normal” for CGT development.

In the Ori Spotlight podcast episode titled, “The CGT developers who adapt new manufacturing techniques early will lead later,” the pair discuss how expectations for advanced therapies are changing and why key operational decisions can’t be left until late-stage development. John highlights the need to bring infrastructure planning, automation, and comparability studies into early development, noting that CGT companies can reduce manufacturing risk by running activities in parallel and investing in platform approaches from the start.

Interested in the full discussion? Tune in to the ‘Ori Spotlight’ podcast to hear the complete conversation.

Click HERE to listen to listen now!